CareTrust REIT, Inc.

▲ Bull Case

• ◆Deploy the dry powder at maintained yields: $3B+ of acquisition capacity at sustained 8.5–9% yields drives FAD/share to ~$2.75 by FY2028E and supports continued 10–12% dividend growth. Multiple holds at 20–21x → $58 3-year target.
• ◆UK platform compounds as a second growth engine: 50–100 additional UK homes through 2028 at 8% blended yields, with operator quality maintained at CQC 'Good' ratings. Validates 'transatlantic healthcare REIT' identity and commands sustained premium multiple.
• ◆SNF sector secular tailwinds underappreciated: Occupancy recovers to 90%+ nationally by 2027; operator coverage rises to 3.2x portfolio-wide. PDPM stability + supply contraction + demographic demand = three secular vectors compounding through 2030.

▼ Bear Case

• ◆Multiple compression on growth deceleration: Acquisition deal flow slows (PE re-enters; cap rates compress); FAD/share growth decelerates to 5–7%; market re-rates from 20x to 13–14x toward OHI/SBRA range. Pure multiple compression alone implies $29–$33 price (-25 to -28%).
• ◆Medicaid reimbursement restructuring: Congressional per-capita caps or block grants with rapid phase-in cuts SNF operator revenues 5–10%; portfolio EBITDARM coverage falls from 2.82x toward 1.8–2.0x; selective rent restructurings required.
• ◆Ensign concentration tail: Despite Ensign's 4.28x coverage today, the 27.6% ABR concentration in a single operator is a structural credit risk that could impair FFO/share and require a dividend growth pause if materialized.

“The active sell-side debate centers on multiple sustainability: is CTRE's 20x forward P/AFFO a structural premium for sector-leading growth + balance sheet + portfolio quality, or a cyclical premium that will mean-revert to the 12–14x SNF peer median once growth decelerates? Bull-side analysts argue the premium is structural — internal management, zero credit losses, dry powder, UK optionality all justify durability of 18–22x. Bear-side analysts argue the 51% YTD run has priced in two years of catalysts; the negative dividend-yield spread vs. Treasuries (~-80 bps) is unsustainable for an income vehicle; multiple compression is a question of 'when,' not 'if.' The reverse-implied math shows the current price embeds only ~3% perpetual dividend growth and ~10% FAD/share growth through FY2030 — internally consistent with the base case, but offering little margin of safety.”

• ◆Q2 2026 earnings + acquisition pipeline color (July–Aug 2026)
• ◆Follow-on UK acquisition announcement (12–18 months)
• ◆Dividend increase (Q2 or Q3 2026 declaration)
• ◆S&P credit rating upgrade (6–12 months; Moody's already upgraded)
• ◆FY2027 guidance initiation (early 2027)
• ◆Operator coverage data update (Q1 each year)

• ◆Multiple compression to peer median (Moderate probability, High severity) — -25 to -42% from spot if multiple re-rates to 12–14x
• ◆Medicaid structural cuts (Low-Moderate probability, Very High severity) — Per-capita caps/block grants compress operator margins
• ◆Ensign concentration event (Very Low probability near-term, Very High severity) — 27.6% ABR concentration represents tail risk despite 4.28x coverage
• ◆Interest-rate re-rise to 5.5%+ (Moderate probability, Moderate-High severity) — Negative dividend-yield spread widens; multiple pressure increases
• ◆Care REIT integration issues (Moderate probability, Moderate severity) — CQC rating downgrades or NHS referral disruption
• ◆CMS minimum staffing rule (Low probability, Moderate severity) — Some operators may struggle; portfolio level manageable